Kornimate/medical-research-clean huggingface dataset:
diagnostic performance and prognostic ability of the qfr

Conditions: Ischemic Heart Disease

Summary: 1. the primary technical endpoint was the diagnostic performance of the qfr against the ffr. 2. the primary clinical endpoint was target vessel failure (tvf) between two groups distributed by a qfr cut-off value of 0.8

the quantitative flow ratio (qfr) is a novel angiography-based tool used to assess functional ischemia caused by coronary stenosis. computation of the fractional flow reserve (ffr) from coronary angiography is based on 3d reconstruction and fluid dynamics algorithms using a modified frame count; therefore, we do not need to induce hyperemia or perform invasive procedures with a pressure wire to measure it. during the past few years, the diagnostic accuracy of the qfr was investigated and showed favorable outcomes. however, data for patients with acute coronary syndrome are lacking. in addition, no data are available for the performance of the qfr in predicting clinical outcomes. we aim to evaluate the diagnostic performance of the qfr versus the ffr and their predictive abilities for clinical outcome in a real-world all-comer population. the catholic imaging and functional research (c-ifr) cohort was designed to evaluate the diagnostic performance and clinical outcome predictive ability of the qfr in consecutive patients undergoing cag and the ffr at 4 major cardiac centers in korea from january 2012 to may 2018. all hospitals (seoul st. mary's hospital, seoul; st. paul's hospital, seoul; incheon st. mary's hospital, incheon; uijeongbu st. mary's hospital, uijeongbu) perform a high volume of percutaneous coronary intervention (pci) procedures, with more than 800 pci procedures performed per year. this qfr registry includes demographic characteristics, clinical information, laboratory data, qfr findings, and ffr findings, with clinical outcome data collected over 4 years (a median of 2 years)

Eligibility criteria:
inclusion criteria: * subject ≥18 years * patients suspected with ischemic heart disease * all-comer patients with sa, ua and ami whose cag results showed intermediate stenosis (50-70%) indicative of physiologic lesions * patients whose target vessels were able to analyze qfr exclusion criteria: patients with insufficient cag data due to reasons below * cag data uploading error * 2 projection angles \<25 degrees apart * only 1 projection angle image exists * images with suboptimal contrast filling * images with too much panning or too much magnification * containing an ostial lesion of the left main coronary artery or right coronary artery * anatomical vessel problems including severe overlap, severe tortuosity, foreshortening, diffuse lesions, additional far distal lesion

Keywords: qfr quantitative flow ratio
bauhinia forficata in diabetic patients

Conditions: Diabetes

Summary: among the plants most used in folk medicine for the treatment of diabetes are the species of the genus bauhinia (fabaceae), popularly known in brazil as "pata-de-vaca". of these, bauhinia forficata has the highest number of studies regarding the hypoglycemic activity. due to this fact it is included in the medicinal plants list of the brazilian public health system. extracts of pata-de-vaca (b. forficata) have been explored both in relation to its chemical composition and its pharmacological potential. from the chemical point of view the main components identified in hydro alcoholic extract of the leaves are o-glycosylated derivatives of kaempferol and quercetin. regarding pharmacological properties preclinical studies have confirmed the hypoglycemic effect and antidiabetic of the hydroalcoholic extract of the leaves of b. forficata. the search for evidence of the alleged anti-diabetic activity of b. forficata in clinical level was performed in only two studies, both with few patients, and questionable methodological quality that used tea as a pharmaceutical form, a fact that allows us to question the validity of data considering the risks of no dose reproducibility ingested by patients during the study. thus the investigators here intend to determine the effects of a standardized extract of b. forficata in the control of patients with diabetes mellitus


Eligibility criteria:
inclusion criteria: * type ii diabetic patients * using oral antidiabetic treatment for at least 3 months * glycated hemoglobin levels \> 7.5% or * fasting glucose levels \>=100mg/dl exclusion criteria: * type 1 diabetes patients * history of cancer under treatment * major cardiovascular event during the last 90 days (eg. stroke, myocardial infarction) * pregnancy * lactation * serious diseases presenting limited short-term prognosis (eg stage iv copd end-stage heart failure) * child b or c cirrhotic patients * patients with chronic renal failure on dialysis
fitlight reliability and acute training effects

Conditions: Athletic Injuries

Summary: the purpose of this study is to assess the reliability of outcomes collected using a speed and cognitive light training system. this study will also be used to understand the effects of brain training on athletic performance using the fitlight system.


Eligibility criteria:
inclusion criteria: * healthy as determined by a physical activity readiness questionnaire * bmi under 30 exclusion criteria: * color-blindness * fractures within the past year * musculoskeletal injury limiting sports activity within the past 6 months * anterior cruciate ligament (acl) injuries within the past 5 years * medical conditions that do not have physician clearance to participate in exercise * history of concussion * diagnosed cognitive impairments * untreated attention deficit/hyperactivity disorder (adhd) or attention deficit disorder (add) * prisoners * pregnant women * smokers

Keywords: reaction time neurocognitive performance agility training
the effects of artificial lighting on affective and core symptoms of eating disorder

Conditions: Anorexia Nervosa; Eating Disorder

Summary: the primary objective of this pilot study is to explore the effect of artificial lighting on affective symptoms, and the secondary aim is to explore the effect of artificial lighting on core symptoms of eating disorders (ed). several lines of evidence, albeit from hypothesis generation studies, suggest that artificial lighting may have a positive effect on well-being, mental health and affective symptoms in ed. the rationale of this study is to investigate the effects of artificial lighting on affective symptoms and cores symptoms of ed in inpatients undergoing weight restoration/treatment for ed. study design: single-blind, controlled, pilot intervention study with circadian light (cl) comparing two cl regimens effects on mood symptoms. planned number of subjects: 16 patients with a icd-10 diagnosis of anorexia nervosa, that completes exposure to at least three weeks of the two different cl regimens (l1 and l2) in any order.

the primary objective of this pilot study is to explore the effect of artificial lighting on affective symptoms, and the secondary aim is to explore the effect of artificial lighting on core symptoms of eating disorders (ed). if an effect is indicated, the study will provide information on how to improve light exposure to ed patients in psychiatric treatment units. in addition, the outcomes may help identify a better system for measurement and adjustment of the specific light variables of colour temperature and light intensity. several lines of evidence, albeit from hypothesis generation studies, suggest that artificial lighting may have a positive effect on well-being, mental health and affective symptoms in ed. this is the rationale to investigate the effects of artificial lighting on affective symptoms and cores symptoms of ed in inpatients undergoing weight restoration/treatment for ed. study design: single-blind, controlled, pilot intervention study with circadian light (cl) comparing two cl regimens effects on mood symptoms. planned number of subjects: 16 patients with a international classification of disorders 10 (icd-10) diagnosis of anorexia nervosa, that completes exposure to at least three weeks of the two different cl regimens (l1 and l2) in any order. location: mental health center ballerup, department 14 (currently department 5). diagnostic inventory: eating disorder examination-questionnaire (ede-q)

Eligibility criteria:
inclusion criteria: 1. primary diagnosis of anorexia nervosa (an) or bulimia nervosa (bn) or eating disorder not otherwise specified (ednos) 2. age ≥18 and \<65 exclusion criteria: 1. forced care 2. non-primary psychiatric disorder other than an, bn, or ednos 3. binge eating disorder 4. somatic unstable condition 5. high suicidal behavior or risk

Keywords: artificial lighting
immunopet targeting trophoblast cell-surface antigen 2 (trop-2) in thyroid cancer

Conditions: Tumor; Solid Tumor; Thyroid Cancer; Positron-Emission Tomography

Summary: the objective of the study is to construct a noninvasive approach 68ga-thp-trop2 vhh pet/ct to detect the trop-2 expression of tumor lesions in patients with thyroid cancer and to identify patients benefiting from trop-2 targeting antibody-drug conjugate treatment.

as a new trophoblast cell-surface antigen 2 (trop-2) targeting pet radiotracer, 68ga-thp-trop2 vhh is promising as an excellent imaging agent applicable to various cancers. in this research, subjects with thyroid cancer or highly suspected recurrence detection underwent contemporaneous 68ga-thp-trop2 vhh and standard-of-care imaging (18f-fdg and 68ga-fapi pet/ct) either for an initial assessment or for metastases or highly suspected recurrence detection. tumor uptake was quantified by the maximum standard uptake value (suvmax). the numbers of positive tumor lesions of standard-of-care imaging and 68ga-thp-trop2 vhh pet/ct were recorded by visual interpretation. the diagnostic accuracy of 68ga-thp-trop2 vhh was calculated and compared to standard-of-care imaging.

Eligibility criteria:
inclusion criteria: * adult patients (aged 18 years or older); * patients with newly diagnosed, highly suspected recurrence or previously treated metastases of thyroid cancer (supporting evidence may include mri, ct, tumor markers, and pathology report); * patients who had scheduled both standard-of-care imaging (18f-fdg and 68ga-fapi pet/ct) and 68ga-thp-trop2 vhh pet/ct scans; * patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the clinical research ethics committee. exclusion criteria: * patients with pregnancy; * the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Keywords: tumor solid positron-emission tomography trop-2 diagnosis
efficacy trial of the fmf connect mobile health intervention

Conditions: Fetal Alcohol Spectrum Disorders

Summary: the purpose of this study is to test a new smartphone "app" for parents/caregivers of children with fetal alcohol spectrum disorder (fasd). the app is called families moving forward (fmf) connect. the goal of the app is to provide parents/caregivers with useful information to help manage their children's condition and obtain peer support.


Eligibility criteria:
inclusion criteria: * biological parent or other primary caregiver (e.g., foster or adoptive parent, relative, legal guardian) of a child with fasd or prenatal alcohol exposure (pae) * the parent/caregiver must be at least 18 years old * the child must between the ages of 3 and 12 years old * the child has a diagnosis of fasd or has confirmed pae * the child has lived with the parent/caregiver for at least 4 months and is expected to remain in the home for at least 1 year * the parent/caregiver lives in the united states * the parent/caregiver has a smartphone or ipad with ios operating system exclusion criteria: * the parent/caregiver is not fluent in english (the fmf connect app and pre-post measures are currently only available in english) * there is another parent/caregiver of the same child or living in the home that is already enrolled in the study (couples are excluded to prevent dependence in the data) * the family has previously received or is currently receiving the therapist-led families moving forward (fmf) program
the impact of holding on stress and bonding in mother-infant pairs during therapeutic hypothermia

Conditions: Hypoxic-Ischemic Encephalopathy; Neonatal Encephalopathy

Summary: this research is being done to try to improve the experience of mothers and babies during therapeutic hypothermia. currently, mothers are not able to hold their baby during hypothermia treatment. mothers have reported that not being able to hold their baby during this time is stressful. additionally, it is known that holding has many benefits for mothers' and babies' psychological and physical health. therapeutic hypothermia is the standard of care. the experimental interventions of this study are to have mothers hold their babies during this treatment, collect saliva samples from mothers and babies, and test the saliva samples for the hormones cortisol and oxytocin. the investigators will test saliva of infants and their mothers before and after holding. the investigators hope to demonstrate decreased cortisol, a marker for stress, and increased oxytocin, a marker for bonding, in infants and mothers while they are held during therapeutic hypothermia.

the inability to hold an infant being treated with therapeutic hypothermia in the neonatal intensive care unit has been subjectively reported by ours and other research groups as a significant source of stress for parents. the investigators aim to assess the impact of holding on endocrinological markers of stress and bonding. specifically, the investigators plan to collect salivary cortisol and oxytocin levels from infants undergoing therapeutic hypothermia and their mothers prior to and immediately after a 30-minute holding period. the investigators hypothesize that measurable increases in salivary oxytocin levels, coinciding with the reported qualitative increased levels of bonding, will be observed after the holding period. the investigators anticipate the reported stress reduction after holding to be quantified by measurable decreases in salivary cortisol levels. the investigators hypothesize these hormone changes will be present in both the mother and the infant when compared to samples taken without the holding intervention.

Eligibility criteria:
inclusion criteria: * gestational age at birth of 35 weeks or greater * absence of clinical or electrographic seizures during the first 24 hours of therapeutic hypothermia * designation as "clinically stable" by the attending neonatologist on service * respiratory status of: room air, nasal cannula, continuous positive airway pressure or intubated on conventional ventilator exclusion criteria: * designation as "clinically unstable" by the a member of the medical team * use of inhaled nitric oxide for persistent pulmonary hypertension of the newborn * high frequency oscillator ventilation * presence of electrographic seizures * use of vasopressors or paralytic agents, presence of chest tubes, wound vacuums, or drains * in utero opiate exposure

Keywords: saliva neonatal encephalopathy hypoxic-ischemic encephalopathy bonding oxytocin stress cortisol
a study of atezolizumab with or without tiragolumab in participants with unresectable esophageal squamous cell carcinoma whose cancers have not progressed following definitive concurrent chemoradiotherapy

Conditions: Esophageal Squamous Cell Carcinoma

Summary: the purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dcrt). participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (arm a), tiragolumab matching placebo plus atezolizumab (arm b), or double placebo (arm c).


Eligibility criteria:
key inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0 or 1 * histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the esophagus * unresectable disease ineligible for curative surgery based on the documented opinion of the qualified medical, surgical or radiation oncologist prior to dcrt and is not expected to undergo tumor resection during the course of the study * dcrt treatment according to regional oncology guidelines for esophageal cancer * representative archival formalin-fixed, paraffin-embedded (ffpe) tumor specimens collected prior to initiation of dcrt * adequate hematologic and end-organ function prior to randomization * women of childbearing potential must remain abstinent or use contraceptive methods with a failure rate of \< 1% per year during the treatment period, for 5 months after the final dose of atezolizumab/placebo, and for 90 days after the final dose of tiragolumab/placebo, whichever is later * men must agree to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agree to refrain from donating sperm during the treatment period and for 90 days after the final dose of tiragolumab/placebo. key exclusion criteria: * prior treatment with cd137 agonists or immune checkpoint blockade therapies, including anti-ctla-4, anti-pd-1, anti-pd-l1 and anti-tigit therapeutic antibodies * any unresolved toxicity of national cancer institute's (nci) common terminology criteria for adverse events (ctcae) grade ≥ 2 from the prior chemoradiation therapy with the exception of irreversible and manageable hearing loss * prior allogeneic stem cell or solid organ transplantation * active or history of autoimmune disease or immune deficiency * history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis * malignancies other than esophageal cancer within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death * treatment with any other investigational agent, including epidermal growth factor receptor (egfr) inhibitors, with therapeutic intent for esophageal cancer prior to randomization.
efficacy and safety of sertraline in the treatment of maintenance hemodialysis patients with depression

Conditions: Efficacy, Team; Adverse Reaction to Drug

Summary: depression is a common mental disorder in patients undergoing maintenance hemodialysis (mhd), which increases the risk of cardiovascular events, hospitalization rates, and mortality, but has not received enough attention from patients and medical staff. sertraline is a selective serotonin reuptake inhibitor with fewer adverse reactions and higher safety compared to other antidepressants. this study aims to investigate the efficacy and safety of sertraline in patients undergoing mhd with depression. this study used a randomized controlled design and evaluated the depression status of the patients using the hamilton depression scale (hamd). mhd patients with comorbid depression were recruited and divided into the treatment group and the control group. the treatment group received sertraline for antidepressant therapy, while the control group did not receive any antidepressant medication. to investigate the efficacy and safety of sertraline before and after intervention.

the hamd, the medication adherence report scale-5 (mars-5), the mini nutritional assessment short-form (mna-sf) and the kidney disease quality of life-36 (kdqol-36) scales were used to evaluate changes in depression status, quality of life, medication adherence and nutritional status before and after the intervention. clinical and laboratory indicators were collected before and after the intervention. adverse reactions during the intervention were also recorded. the initial dose ranged from 25 to 50 mg, taken orally once daily, and the dosage was adjusted based on the patient's response to the medication. in the control group, no antidepressant treatment was given.

Eligibility criteria:
inclusion criteria: 1. long-term mhd patients in the blood purification center of our hospital, older than 18 years old, maintenance dialysis for at least 3 months, 2-3 times a week, 3-4.5 hours each time; 2. meet the ckd5 diagnostic criteria; 3. the cardiopulmonary function was relatively stable before enrollment, and the life expectancy was more than 1 year; 4. the clinical data were basically complete; 5. consciousness, intelligence is normal, can understand the questionnaire content. exclusion criteria: 1. communication, communication disorders or other psychiatric history; 2. combined with active pulmonary tuberculosis, aids, severe infection patients; 3. pregnant or lactating women; 4. those who are taking antidepressants or other antipsychotic drugs; 5. unable or unwilling to cooperate with the researcher.

Keywords: hemodialysis depression sertraline efficacy safety
impact of a procedure for the information and active participation of the patient in the primary care prescription of antihypertensives

Conditions: Patients on Anti-hypertensive Medication

Summary: adverse drug events (ades) are responsible for 3.6% of the hospitalisations in france. 50% of these ades could be preventable. cardiovascular drugs are frequently involved in ades. a common underlying factor of such events is inadequate communication between patients and medical personnel. general practitioners (gp) often initiate the treatment of hypertension, being generally the first prescribers of these medications. 12.6% of the patients present an ade with hypertensive drug after 3 months. the inpact procedure is a tool to facilitate communication in order to improve patient safety in primary care. in the context of the primary care prescription of an antihypertensive drug, the gp informs the patient about hypertension, cardiovascular risk, and the benefits and risks of antihypertensive drugs, which helps the patient to detect and declare situations involving a heightened risk of antihypertensive-related ades. the aim of the inpact study is to evaluate the efficiency of the inpact intervention in primary care.

a stepped wedge cluster randomized study, with 8 clusters and 5 periods of 3 months each. each cluster is composed of about ten general practitioners. the inpact intervention will not be presented to the first patients recruited by each general practitioner, whereas it will be presented to all their last patients. the period of intervention introduction by each general practitioner will be randomized amongst the 5 periods.

Eligibility criteria:
inclusion criteria: * patient monitored for essential hypertension requiring a first prescription, a renewal or a change of antihypertensive drug treatment * patient with the ability to understand and express themselves in french * patient accepting to communicate his phone number and accepting a telephone survey within the fourth month following its inclusion in the study. exclusion criteria : * patient with a psychiatric disorder or a progressive dementia. * patient with hypertension in pregnancy or secondary hypertension. * patient with an acute hypertensive crisis. * patient under guardianship. * patient who is likely to move or may have an irregular follow up within 6 months following its inclusion in the study.

Keywords: patient information and active participation patient safety health education adverse drug event primary care antihypertensive drugs